Press Releases

May 14, 2021
Durable and Clinically Meaningful Responses Maintained at More than 2.5 and 3 Years Post-Treatment in Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC Next-Generation HeLa Producer Cell Line Manufacturing Platform Results in Significant Product Yield Increases NOVATO, Calif., May 14, 2021
Read More
Apr 28, 2021
NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will
Read More
Displaying 11 - 20 of 31